Glimepiride-KV tablets 4 mg No. 30

Glimepiride-KV tablets are prescribed for the treatment of type 2 diabetes in adults when blood glucose levels cannot be adequately maintained by diet, exercise, and weight loss alone.

Composition

Active ingredient: glimepiride.

1 tablet contains glimepiride 2 mg or 3 mg or 4 mg.

Excipients: lactose monohydrate, microcrystalline cellulose, povidone, sodium lauryl sulfate, crospovidone, magnesium stearate.

Contraindication

Method of application

The dosage depends on the results of blood and urine glucose tests.

The initial dose is 1 mg (1/2 tablet of 2 mg) of glimepiride per day. If this dose allows to achieve disease control, it should be used for maintenance therapy.

If glycemic control is not optimal, the dosage should be increased to 2 or 3 or 4 mg glimepiride per day gradually (at intervals of 1-2 weeks).

A dose of more than 4 mg per day gives better results only in some cases. The maximum recommended dose is 6 mg of Glimepiride-KV per day.

If the maximum daily dose of metformin does not provide adequate glycemic control, the patient can be started on concomitant therapy with glimepiride.

Features

Pregnant women

Abnormal blood glucose levels during pregnancy may increase the risk of congenital malformations and perinatal mortality. Therefore, the amount of glucose in the blood of a pregnant woman should be carefully monitored in order to avoid teratogenic risk. A pregnant woman with diabetes should be transferred to insulin. Women with diabetes should inform their doctor about the planned pregnancy for correction of treatment and transfer to insulin.

Children

Existing data on the safety and efficacy of the drug in children are insufficient, therefore its use in this category of patients is not recommended.

Drivers

No effects on the ability to drive or use machines have been reported and are not expected due to homeopathic dilutions.

Overdose

Not observed and not expected due to homeopathic dilutions.

Side effects

The ability to concentrate and the speed of reaction may be reduced due to hypoglycemia or hyperglycemia or, for example, due to impaired vision.

Interaction

The simultaneous use of Glimepiride-KV with certain drugs can cause both weakening and strengthening of the hypoglycemic effect of glimepiride. Therefore, other drugs should be taken only with the consent (or prescription) of a doctor. Glimepiride is metabolized by cytochrome P450 2C9 (CYP2C9). It is known that due to the simultaneous use of inducers (e.g. rifampicin) or inhibitors of CYP2C9 (e.g. fluconazole) this metabolism may change. The results of the in vivo interaction study showed that fluconazole, one of the strongest inhibitors of CYP2C9, increases the AUC of glimepiride approximately twice. The existence of these types of interactions is evidenced by the experience of using Glimepiride-KV and other sulfonylurea derivatives.

Storage conditions

Store in original packaging. Keep out of reach of children.

Shelf life: 3 years.